Bidirectional Changes in Myocardial 18 F-Fluorodeoxyglucose Uptake after Human Ventricular Unloading
Tiberiu A. Pana,Jainy Savla,Ingrid Kepinski,Adam Fairbourn,Aneela Afzal,Pradeep Mammen,Mark Drazner,Rathan M. Subramaniam,Chao Xing,Kathryn A. Morton,Stavros G. Drakos,Vlad G. Zaha,Hesham A. Sadek
DOI: https://doi.org/10.1161/circulationaha.121.056278
IF: 37.8
2022-01-01
Circulation
Abstract:HomeCirculationVol. 145, No. 2Bidirectional Changes in Myocardial 18F-Fluorodeoxyglucose Uptake After Human Ventricular Unloading Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessLetterPDF/EPUBBidirectional Changes in Myocardial 18F-Fluorodeoxyglucose Uptake After Human Ventricular Unloading Tiberiu A. Pana, MBChB, MRes, Jainy Savla, MD, Ingrid Kepinski, BS, Adam Fairbourn, BS, Aneela Afzal, BS, Pradeep Mammen, MD, Mark Drazner, MD, Rathan M. Subramaniam, MBBS, BMedSc, MClinEd, MPH, PhD, MBA, Chao Xing, PhD, Kathryn A. Morton, MD, Stavros G. Drakos, MD, PhD, Vlad G. Zaha, MD, PhD and Hesham A. Sadek, MD, PhD Tiberiu A. PanaTiberiu A. Pana https://orcid.org/0000-0002-1423-8111 Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, United Kingdom (T.A.P.). Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Jainy SavlaJainy Savla Department of Internal Medicine/Cardiology, University of Washington, Seattle (J.S.). Search for more papers by this author , Ingrid KepinskiIngrid Kepinski Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Adam FairbournAdam Fairbourn Department of Radiology (A.F., R.M.S.); Search for more papers by this author , Aneela AfzalAneela Afzal https://orcid.org/0000-0002-0073-8166 Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Pradeep MammenPradeep Mammen https://orcid.org/0000-0001-5688-7091 Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Mark DraznerMark Drazner https://orcid.org/0000-0003-3054-4757 Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Search for more papers by this author , Rathan M. SubramaniamRathan M. Subramaniam Department of Radiology (A.F., R.M.S.); Search for more papers by this author , Chao XingChao Xing https://orcid.org/0000-0002-1838-0502 Eugene McDermott Center for Human Growth and Development (C.X.); Department of Bioinformatics (C.X.); Department of Population and Data Sciences (C.X.); Search for more papers by this author , Kathryn A. MortonKathryn A. Morton Department of Radiology and Imaging Sciences (K.A.M.), University of Utah School of Medicine, Salt Lake City. Search for more papers by this author , Stavros G. DrakosStavros G. Drakos https://orcid.org/0000-0002-1223-327X Division of Cardiovascular Medicine (S.G.D.), University of Utah School of Medicine, Salt Lake City. Search for more papers by this author , Vlad G. ZahaVlad G. Zaha Correspondence to: Vlad G. Zaha, MD, PhD, or Hesham A. Sadek, MD, PhD, 5323 Harry Hines Blvd. Cardiology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390. Email E-mail Address: [email protected] or E-mail Address: [email protected] https://orcid.org/0000-0003-4878-891X Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Harold C. Simmons Comprehensive Cancer Center (V.G.Z.); Advanced Imaging Research Center (V.G.Z.); Biomedical Engineering Program, Graduate School of Medical Sciences (V.G.Z.); Search for more papers by this author and Hesham A. SadekHesham A. Sadek Cardiology Division, Department of Internal Medicine (T.A.P., I.K., A.A., P.M., M.D., V.G.Z., H.A.S.); Department of Molecular Biology (H.A.S.); Hamon Center for Regenerative Medicine (H.A.S.), University of Texas Southwestern Medical Center, Dallas. Search for more papers by this author Originally published10 Jan 2022https://doi.org/10.1161/CIRCULATIONAHA.121.056278Circulation. 2022;145:151–154Left ventricular assist devices (LVADs) are lifesaving interventions, especially as the number of advanced heart failure patients requiring circulatory support increases. LVADs decrease mechanical and metabolic demands, which may promote myocardial regeneration.1 Recent studies2,3 demonstrate appreciable functional recovery resulting in successful ventricular assist device explantation in a number of patients; typically, however, only a small percentage of patients with LVADs can fully recover.4 Therefore, it is important to define the fundamental mechanisms of myocardial recovery in response to LVAD. In the present study, we hypothesized that LVAD support stimulates myocardial regeneration as reflected by increased metabolic activity in previously nonviable regions of failing myocardium. Specifically, we set out to determine whether long-term LVAD mechanical unloading results in metabolic activation of quiescent myocardial regions by prospectively and longitudinally examining myocardial 18F-fluorodeoxyglucose (FDG) uptake in patients with end-stage heart failure after LVAD implantation.Patients 18 to 70 years of age with dilated or ischemic cardiomyopathy undergoing LVAD implantation within 3 to 6 months and with a preimplantation left ventricular ejection fraction ≤40% at the University of Texas Southwestern Medical Center were eligible to be included in the study. Exclusion criteria included: hypertrophic or radiation-induced cardiomyopathy, end-stage renal failure, hepatic cirrhosis, patients requiring right ventricular assist device support, those who developed LVAD complications (pump failure or LVAD thrombosis requiring exchange), and those with right ventricular failure requiring chronic inotropes. Pregnant patients were also excluded. This study was approved by the University of Texas Southwestern Medical Center Institutional Review Board (STU 102015-085) and was conducted in accordance with the Declaration of Helsinki (1964) and later amendments. The data that support the findings of this study are available from the corresponding author on reasonable request.A standard clinical myocardial viability positron emission tomography (PET) imaging protocol was used with injection of 0.15 mCi/kg of FDG and PET imaging performed 60 minutes afterward. Baseline FDG-PET scans were undertaken no more than 6 months from LVAD implantation, and follow-up FDG-PET scans were performed every 6 months until a maximum of 4 subsequent scans was achieved, the patient underwent heart transplantation, or the patient died. Image postprocessing was performed with MIM Software and the Matlab Image Processing Toolbox.Metabolic activity of myocardial areas with little or no metabolic activity at baseline regions of interest were defined as myocardial areas exhibiting less than the 5th percentile of FDG uptake on baseline scans. The distributions of pixel intensities were then compared between the regions of interests obtained from baseline and follow-up scans. Metabolic reactivation was quantified as the ratio between the areas under the intensity histograms at the follow-up scans that exceeded the 5th percentile thresholds and the total area under the intensity histogram of the quiescent areas at the baseline scan. Pairwise 2-sample Kolmogorov–Smirnov tests between baseline and each subsequent time point for each patient were performed to detect distributional changes. A total of 4 consenting eligible patients were included in the study, ranging from 31 to 59 years of age. Patients 1, 3, and 4 had been diagnosed with nonischemic cardiomyopathy, whereas patient 2 had been diagnosed with ischemic cardiomyopathy. Patients 2 and 3 had preexisting hypertension. All patients were receiving evidence-based heart failure disease–modifying pharmacological therapy. Of the 4 patients, 2 underwent 4 consecutive scans before cardiac transplant and 2 underwent 2 consecutive scans only. LVAD flow ranged between 3.4 to 5.9 L/min at baseline and remained relatively constant during the study period for each patient. In patients 1 and 2, LVAD speed was 2660 rotations per minute, whereas LVAD speeds in patients 3 and 4 were 9200 and 5500 rotations per minute, respectively. LVAD speeds remained constant during the study period for each patient.From baseline to follow-up scans, we found that 2 patients exhibited overall decreases in FDG uptake which predominantly affected the left ventricle lateral segments; 1 patient exhibited little change in FDG uptake during the study duration, and 1 patient exhibited overall increases in FDG uptake distributed across all myocardial segments (Figure [A and B]). Interestingly, all participants exhibited some degree of increase in FDG uptake in areas of previous metabolic inactivity at baseline, suggestive of possible myocardial regeneration. There was a significant degree of heterogeneity among participants, however, as a 1.87% to 23.80% increase in FDG uptake was observed in quiescent areas compared to baseline (Figure [C]). Inversely, analysis of FDG uptake in myocardial areas that were metabolically active at baseline showed that 2 patients exhibited significant decreases in FDG uptake, 1 exhibited increased FDG uptake, and 1 exhibited little change.Download figureDownload PowerPointFigure. Relative intensity of 18F-fluorodeoxyglucose (FDG) myocardial uptake by serial cardiac FDG positron emission tomography (FDG-PET) scans and displayed as polar maps. A, Diagrams showing the distribution of the different LV segments according to the American Heart Association 16-segment model are displayed over the polar maps (0 indicates no uptake; 100 indicates strong uptake). B, Polar maps displaying the relative change in the relative intensity of myocardial FDG uptake (–50 indicates a 50% decrease; +50 indicates a 50% increase) between baseline and follow-up time points, measured by serial cardiac FDG-PET scans. Red indicates regions with increased uptake from one time point to the next, whereas blue color indicates regions with decreased uptake from one time point to the next. Plots show the distribution of the different left ventricle segments according to the American Heart Association 16-segment model, and are displayed over the polar maps. C, Frequency histograms displaying the distribution of the FDG myocardial uptake in the areas of the myocardium exhibiting low FDG uptake (<5th percentile of the left ventricle FDG uptake levels at the baseline scan), exhibited as pairwise comparisons between the baseline and the follow-up (6, 12, 18 months) scans for each patient. The yellow dashed line indicates the 5th percentile of FDG uptake on the baseline scan for each patient. A rightward shift in the intensity distribution histogram represents an overall increase in FDG uptake, whereas a leftward shift represents an overall decrease in FDG uptake. The percentages displayed represent the ratio between the areas under the intensity histograms at the follow-up scans exceeding the 5th percentile thresholds and the area under the intensity histogram of the quiescent regions at the baseline scan. The horizontal axis represents the voxel-level relative intensity of FDG uptake normalized to the peak FDG uptake in metabolically active areas. The P values were obtained from pairwise 2-sample Kolmogorov–Smirnov tests for equality of distribution between baseline and each subsequent time point for each patient (P values <0.001). D, Frequency histograms displaying the total distribution of the FDG myocardial uptake exhibited as pairwise comparisons between baseline and follow-up (6, 12, 18 months) scans for each patient. A rightward shift in the intensity distribution histogram represents an overall increase in FDG uptake, whereas a leftward shift represents an overall decrease in FDG uptake.Although a recent, elegantly done study found no improvement in myocardial viability after a median 2.1 months of LVAD support,5 the present study is differentiated by a longer duration on LVAD which was previously shown to impact cardiomyocyte cell cycle reentry.1In conclusion, this prospective FDG-PET imaging study of 4 end-stage heart failure patients demonstrates that long-term mechanical unloading of the left ventricle is associated with bidirectional metabolic changes in the myocardium and a heterogenous, yet measurable, increase in viability of previously quiescent myocardial regions. However, a major limitation of this study is the small number of patients, and thus further studies are needed to determine the effect of mechanical unloading on myocardial viability.Article InformationData sharing: The data that support the findings of this study and research materials, as well as experimental procedures and protocols, are available from the corresponding author upon reasonable request.Sources of FundingThis work is supported by funds from the Center for Regenerative Science and Medicine at the University of Texas Southwestern and the Leducq Foundation (Redox Leducq). Dr Pana received the Academy of Medical Sciences INSPIRE International Scholarship 2019 to perform the research.Nonstandard Abbreviations and AcronymsFDG18F-fluorodeoxyglucoseLVADleft ventricular assist devicePETpositron emission tomographyDisclosures None.FootnotesThis manuscript was sent to Mauro Giacca MD, PhD for review by expert referees, editorial decision, and final disposition.For Sources of Funding and Disclosures, see page 152.Correspondence to: Vlad G. Zaha, MD, PhD, or Hesham A. Sadek, MD, PhD, 5323 Harry Hines Blvd. Cardiology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390. Email vlad.[email protected]edu or hesham.[email protected]eduReferences1. Canseco DC, Kimura W, Garg S, Mukherjee S, Bhattacharya S, Abdisalaam S, Das S, Asaithamby A, Mammen PP, Sadek HA. Human ventricular unloading induces cardiomyocyte proliferation.J Am Coll Cardiol. 2015; 65:892–900. doi: 10.1016/j.jacc.2014.12.027CrossrefMedlineGoogle Scholar2. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the reversal of heart failure.N Engl J Med. 2006; 355:1873–1884. doi: 10.1056/NEJMoa053063CrossrefMedlineGoogle Scholar3. Birks EJ, Drakos SG, Patel SR, Lowes BD, Selzman CH, Starling RC, Trivedi J, Slaughter MS, Alturi P, Goldstein D, et al.. Prospective multicenter study of myocardial recovery using left ventricular assist devices (RESTAGE-HF [Remission from Stage D Heart Failure]): medium-term and primary end point results.Circulation. 2020; 142:2016–2028. doi: 10.1161/CIRCULATIONAHA.120.046415LinkGoogle Scholar4. Wever-Pinzon O, Drakos SG, McKellar SH, Horne BD, Caine WT, Kfoury AG, Li DY, Fang JC, Stehlik J, Selzman CH. Cardiac recovery during long-term left ventricular assist device support.J Am Coll Cardiol. 2016; 68:1540–1553. doi: 10.1016/j.jacc.2016.07.743CrossrefMedlineGoogle Scholar5. Gupta DK, Skali H, Rivero J, Campbell P, Griffin L, Smith C, Foster C, Claggett B, Glynn RJ, Couper G, et al.. Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device.J Heart Lung Transplant. 2014; 33:372–381. doi: 10.1016/j.healun.2014.01.866CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails January 11, 2022Vol 145, Issue 2Article InformationMetrics © 2021 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.121.056278PMID: 35007159 Originally publishedJanuary 10, 2022 Keywordsprospective studiesfluorodeoxyglucose F18heart-assist devicespositron-emission tomographymyocardiumPDF download Advertisement SubjectsCardiomyopathyHeart FailureRemodeling